Dr. Thomas N. Hoffmann, M.D.
Rheumatology (Rheumatology Physician)
- Medicare participating
At a glance
- Medical school
- Uniformed Services Uhs Fe Hebert School of Med (2004)
- Years since graduation
- 22
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 349
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2004Medical school: Uniformed Services Uhs Fe Hebert School of Med
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Rheumatology Physician primary
HI license MD 13788 -
Internal Medicine Physician
HI license MDR 4634
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Guadalupe Regional Medical Center Seguin, TX
- Connally Memorial Medical Center Floresville, TX
Medical groups
- Rheumatology Solutions PLLC (3 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 349
- Services billed
- 45,594
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 32,800 | 28 |
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 3,050 | 20 |
| Injection, denosumab, 1 mg | 2,040 | 25 |
| Established patient office or other outpatient visit, 30-39 minutes | 508 | 230 |
| Injection of drug or substance under skin or into muscle | 180 | 49 |
| Established patient office or other outpatient visit, 20-29 minutes | 157 | 104 |
| New patient office or other outpatient visit, 45-59 minutes | 82 | 82 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 51 | 29 |
| Administration of chemotherapy into vein, 1 hour or less | 27 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 16 companies reported 158 payments worth $3,752 in total to this clinician.
| Amgen Inc. | $728 |
|---|---|
| AbbVie Inc. | $629 |
| UCB, Inc. | $521 |
| Janssen Biotech, Inc. | $477 |
| Novartis Pharmaceuticals Corporation | $343 |
| AstraZeneca Pharmaceuticals LP | $260 |
| Pfizer Inc. | $147 |
| GlaxoSmithKline, LLC. | $144 |
| Food and Beverage | $3,752 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.